



Commentary

Food Fortification With Folic Acid for Prevention of Spina Bifida and Anencephaly: The Need for a Paradigm Shift in Evidence Evaluation for Policy-Making

Homero Martinez*, Helena Pachón, Vijaya Kancharla, and Godfrey P. Oakley, Jr.

* Correspondence to Dr. Homero Martinez, Global Technical Services Unit, Nutrition International, 180 Elgin Street, Suite 1000, Ottawa, ON K2P 2K3, Canada (e-mail: hmartinez@nutritionintl.org).

Initially submitted November 18, 2020; accepted for publication March 9, 2021.

Context-specific evidence evaluation is advocated in modern epidemiology to support public health policy decisions, avoiding excessive reliance on experimental study designs. Here we present the rationale for a paradigm shift in evaluation of the evidence derived from independent studies, as well as systematic reviews and meta-analyses of observational studies, applying Hill's criteria (including coherence, plausibility, temporality, consistency, magnitude of effect, and dose-response) to evaluate food fortification as an effective public health intervention against folic acid-preventable (FAP) spina bifida and anencephaly (SBA). A critical appraisal of evidence published between 1983 and 2020 supports the conclusion that food fortification with folic acid prevents FAP SBA. Policy-makers should be confident that with mandatory legislation, effective implementation, and periodic evaluation, food fortification assures that women of reproductive age will safely receive daily folic acid to significantly reduce the risk of FAP SBA. Current evidence should suffice to generate the political will to implement programs that will save thousands of lives each year in over 100 countries.

anencephaly; folic acid; food fortification; low- and middle-income countries; neural tube defects; spina bifida

Abbreviations: FAP, folic acid-preventable; NTD, neural tube defect; RCT, randomized controlled trial; SBA, spina bifida and anencephaly.

Editor's note: *The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the American Journal of Epidemiology.*

Spina bifida and anencephaly are major neural tube defects (NTDs) that affect pregnancies worldwide. NTDs are a leading cause of stillbirths and under-5 (under age 5 years) child mortality in high-, middle-, and low-income countries (1). Based on scientific evidence from randomized controlled trials (RCTs) (2–4), nonrandomized intervention trials (5, 6), and observational studies (7, 8), the US Public Health Service recommended in 1992 that all women capable of becoming pregnant consume 400 µg of folic acid (vitamin B₉) per day to lower the risk of NTDs, specifically folic acid-preventable (FAP) spina bifida and anencephaly (SBA) (9). While this primary-prevention recommendation may be met through timely consumption

of daily supplements, a public health approach based on large-scale fortification of staple foods with folic acid has been determined to be more effective (10).

Policies of mandatory food fortification with folic acid started in the United States, Canada, Costa Rica, and Oman in the late 1990s (11–15), followed by South Africa, Chile, and Australia in the 2000s (16–18). Currently, about 80 countries have mandatory folic acid food fortification programs (19). It is estimated that effective mandatory folic acid food fortification programs prevented 18% of all potential FAP SBA cases worldwide in 2017 (20) and 22% of cases worldwide in 2019 (21). Surveillance studies in countries without mandatory policies for folic acid fortification report an average NTD prevalence range reflecting 10–20 cases per 100,000 births in high-income countries and 40–130 cases per 100,000 births in low- and middle-income countries, while the lowest prevalence is reported in countries with effective fortification—consistently about 5 cases per

100,000 births (22, 23). From a public health perspective, this excessively high prevalence of FAP SBA in countries without folic acid fortification of food staples, especially low- and middle-income countries, is equivalent to a highly preventable epidemic.

Despite multiple studies with findings that support the effectiveness of folic acid fortification in improving folate status among women of reproductive age (24–26) and reducing the prevalence of NTDs (27), some policy-makers in countries without folic acid fortification programs are skeptical of implementing fortification. The skepticism arises from a concern that the evidence does not come from RCTs, the type of study considered to provide the highest-quality evidence for evaluation of causation and efficacy (28). However, since previous RCTs have unequivocally established that folic acid prevents NTDs (2–4), it would be unethical to conduct new ones. A new RCT would require folic acid to be withheld from one group of reproductive-age women involved in the study and, as a result, would put those women at risk of an FAP SBA pregnancy.

In this commentary, we suggest a paradigm shift away from traditional evidence evaluation schema, which are more applicable to clinical decisions but less relevant in guiding public health decisions, to support the protective effect of large-scale folic acid food fortification in the prevention of FAP SBA.

THE NEED FOR A PARADIGM SHIFT

Traditionally, evidence-based medicine has long relied on RCTs as the preferred study design for informing clinical decisions. RCTs control for potential bias and confounding when assessing impact (efficacy) better than studies with nonexperimental designs (29). Given that different study designs support statistical interpretations ranging from association to causal inferences, clinicians have proposed an evidence-based pyramid that places study designs along a continuum: Weaker evidence is placed lower on the hierarchy (the base of the pyramid), and stronger evidence is placed higher (coming closer to the top) (30). Systematic reviews and meta-analyses are assumed to provide the highest level of evidence (31).

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group developed an approach with which to guide the rating of the quality of evidence from systematic reviews to inform guidelines for both clinical and public health questions (32). An important aspect of the Working Group's approach is the recognition that study design alone may not account for the risk of bias. Instead, they recommend focusing on the quality of data collection, the magnitude of the effect, the dose-response gradient, and control of potential biases in order to assess the strength of the contribution made by a study. The World Health Organization and the Cochrane Collaboration have both adopted this approach to support their recommendations (32). In addition, depending on the kind of decision to be made (i.e., medical treatment, clinical prognosis, or decisions about public health effectiveness), the pyramid of evidence may vary, giving greater weight to specific study

designs (30). Therefore, a retrospective cohort study or case-control study initially evaluated as providing a “low quality” rating may be upgraded if, for example, the magnitude of the treatment effect is very large and if there is evidence of a dose-response relationship or adequate control for plausible biases (33, 34). Murad et al. (35) have further proposed that it is important to evaluate the quality of the evidence contributing to systematic reviews and meta-analyses before placing these designs at the top of the evidence pyramid.

For several years, different authors in the fields of epidemiology and public health have proposed that, when evaluating the evidence available for guiding public health decision-making, there is a need to move beyond the evidence-based pyramid (36–40). Sir Austin Bradford Hill, one of the pioneers of modern epidemiology, noted that the evaluation of data for making causal inferences should be rigorous. Hill proposed a number of assessment criteria that have been used extensively in establishing causality from observational studies (41). In a recent evaluation of Hill's criteria, Lucas and McMichael supported the value of evidence from observational studies; they stated that most epidemiologic research is nonexperimental and conducted in an “inherently ‘noisy’ environment in free-living populations” (42, p. 792). They underlined the challenges to controlling for potential confounding variables in settings which usually have less opportunity to do so than RCTs (42). Stoltzfus (38) has highlighted several limitations of RCT designs in providing information for guiding public health nutrition interventions, supporting the need to consider mechanistic theories when evaluating the strength of the evidence used to inform public health guidance. Similarly, Vandembroucke et al. pushed for using a pluralistic approach to evaluate causal evidence, underscoring that “the important causal questions are asked not within studies, but between them” (39, p. 1785). Commenting on a recent series of papers on the future of epidemiology, Diez Roux (36) concluded that observational studies now stand to provide the evidence needed in population health due to lack of feasibility and other inherent limitations of RCTs. In implementing evidence-based policies, an important but often overlooked consideration is the likelihood of harm from not assuming causality and making no change in current policy. As Frieden points out, “waiting for more data is often an implicit decision not to act” (37, p. 472).

SIR BRADFORD HILL'S CRITERIA FOR INFERRING CAUSALITY

In evaluating the evidence related to the protective effect of folic acid fortification on FAP SBA, it is important to address 6 of Hill's causal criteria, including coherence, plausibility, temporality, consistency, magnitude of effect, and dose-response. Drawing both from single-site observational studies and from systematic reviews and meta-analyses, the effectiveness of folic acid fortification in reducing the risk of FAP SBA is clear.

The reduction in FAP SBA in response to an improvement in red blood cell folate levels postfortification is both *coherent* and *plausible* with our current knowledge of the

biological mechanisms related to folate metabolism and its role in DNA synthesis and methylation processes that help regulate cell synthesis and growth, which are critical during the period when the neural tube is closing (43). Observational studies carried out in different countries (Cameroon, Chile, Fiji, Tanzania) have documented improvements in blood folate levels and reductions in NTDs (17, 44–46).

Evidence from pre- and postfortification studies (Canada, Chile, Costa Rica, Iran, South Africa, United States) also shows a *temporal* relationship between improvements in population folate status following implementation of fortification programs and subsequent reductions in the prevalence of FAP SBA (14, 17, 47–52).

The *magnitude of the protective effect* of folic acid fortification is more pronounced in regions with high prefortification prevalence of NTDs. For example, in Canada, where the prevalence of NTDs prefortification was known to be higher in eastern provinces and lower in western provinces, reductions in NTDs postfortification were higher in the former (38.0 cases/10,000 births) and lower in the latter (2.1 cases/10,000 births) (53). Similar results have been found elsewhere (49, 54). On average, a meta-analysis by Keats et al. (26) documented a protective effect against NTDs (pooled odds ratio = 0.59, 95% confidence interval: 0.49, 0.70). Theoretical models predict that the lowest prevalence of NTDs observed in populations where maternal red blood cell folate concentration is above the optimal cutoff of 906 nmol/L recommended by the World Health Organization (55) to achieve the maximum protection against NTDs is approximately 5–6 cases per 10,000 births (56), as has actually been found in different countries (14, 49, 54).

Studies carried out in various countries have shown a *consistent* (i.e., repeatedly observed in different studies, in different settings, and at different times) protective effect against FAP SBA through folic acid fortification, including studies conducted in Argentina, Australia, Brazil, Canada, Chile, Costa Rica, Iran, Jordan, Oman, Peru, Saudi Arabia, South Africa, and the United States (24, 57). The systematic review and meta-analysis by Keats et al. (26), which included 16 national fortification programs, found that maize and/or wheat-flour fortification with adequate levels of folic acid over a period of 1–5 years resulted in significant increases in serum folate levels among women of reproductive age, as well as a significant reduction in the prevalence of folate deficiency (relative risk = 0.20, 95% confidence interval: 0.15, 0.25).

Research has documented a *dose-response* relationship between 1) folate/folic acid consumption and serum and red blood cell folate levels (17, 18, 45, 48, 58–65); 2) maternal red blood cell folate concentrations and percent reduction in the prevalence of FAP SBA (10); and 3) voluntary (partial) fortification implementation and mandatory (full) implementation and reduction in FAP SBA prevalence, demonstrated both in single-site studies (52–54, 66) and in a systematic review and meta-analysis of 179 studies (27). Atta et al. (27) found that the pooled total prevalence of spina bifida in countries with mandatory folic acid fortification was 1.5 times lower than that in countries with voluntary fortification or no fortification.

Evidence presented in this commentary on folic acid's protective role in prevention of FAP SBA is informed by experimental, quasi-experimental, and observational study designs in populations worldwide. Thus, the overall target validity (a joint measure of both internal and external validity) of the effectiveness of fortification is high and should encourage policy-makers to implement this intervention (67).

CONCLUSION

In summary, as a team of nutrition researchers and epidemiologists with multiple years of experience in food fortification and FAP SBA, we advocate a shift towards context-specific evidence evaluation and avoidance of excessive reliance on hierarchical models of causal evaluation based predominantly on RCTs, which can be less than optimal when guiding public health interventions for preventing FAP SBA. In this commentary, we have aimed to convey to public health advocates and nutrition policy-makers, especially in low- and middle-income countries, that there are robust and consistent data from both individual and pooled studies that support folic acid fortification as an effective public health intervention for reducing the occurrence and recurrence of FAP SBA (20). Policy-makers should be confident that with mandatory legislation and effective implementation allowing periodic evaluation, food fortification assures that women of reproductive age will receive the daily folic acid needed for healthy pregnancy and significantly reduces the risk of FAP SBA. Skepticism and inaction hinder political will, cost thousands of lives each year globally, cause unnecessary suffering to families, and place an avoidable burden on health-care systems. A change in paradigm can counter skepticism and clarify that large-scale food fortification—a proven and highly cost-effective intervention already recognized as one of the greatest public health achievements of the past century—is the most effective measure in accelerating the global prevention of FAP SBA (68–70).

ACKNOWLEDGMENTS

Author affiliations: Global Technical Services Unit, Nutrition International, Ottawa, Ontario, Canada (Homero Martinez); Hospital Infantil de México Federico Gómez, Mexico City, Mexico (Homero Martinez); Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States (Helena Pachón); Food Fortification Initiative, Atlanta, Georgia, United States (Helena Pachón); and Center for Spina Bifida Prevention, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States (Vijaya Kancherla, Godfrey P. Oakley, Jr.).

We thank Jessie Genoway for editing the final draft of this article. She received no compensation.

Conflict of interest: none declared.

REFERENCES

1. Christianson A, Howson CP, Modell B. *March of Dimes Global Report on Birth Defects: The Hidden Toll of Dying and Disabled Children*. White Plains, NY: March of Dimes Birth Defects Foundation; 2006. http://www.marchofdimes.com/downloads/Birth_Defects_Report-PF.pdf. Accessed December 21, 2020.
2. Czeizel AE, Dudás I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. *N Engl J Med*. 1992;327(26):1832–1835.
3. Laurence KM, James N, Miller MH, et al. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. *Br Med J (Clin Res Ed)*. 1981;282(6275):1509–1511.
4. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet*. 1991;338(8760):131–137.
5. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. *Lancet*. 1983;1(8332):1027–1031.
6. Vergel RG, Sanchez LR, Heredero BL, et al. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. *Prenat Diagn*. 1990;10(3):149–152.
7. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. *JAMA*. 1989;262(20):2847–2852.
8. Mulinare J, Cordero JF, Erickson JD, et al. Periconceptional use of multivitamins and the occurrence of neural tube defects. *JAMA*. 1988;260(21):3141–3145.
9. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. *MMWR Recomm Rep*. 1992;41(RR-14):1–7.
10. Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects: implications for prevention. *JAMA*. 1995;274(21):1698–1702.
11. Alasfoor D, Elsayed MK, Mohammed AJ. Spina bifida and birth outcome before and after fortification of flour with iron and folic acid in Oman. *Eastern Med Health J*. 2010;16(5):533–538.
12. Centers for Disease Control and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects—1983–1991. *MMWR Morb Mortal Wkly Rep*. 1991;40(30):513–516.
13. Oakley GP Jr. The scientific basis for eliminating folic acid-preventable spina bifida: a modern miracle from epidemiology. *Ann Epidemiol*. 2009;19(4):226–230.
14. Ray JG, Meier C, Vermeulen MJ, et al. Association of neural tube defects and folic acid food fortification in Canada. *Lancet*. 2002;360(9350):2047–2048.
15. Tacsan Chen L, Rivera MA. The Costa Rican experience: reduction of neural tube defects following food fortification programs. *Nutr Rev*. 2004;62(6):S40–S43.
16. Brown RD, Langshaw MR, Uhr EJ, et al. The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population. *Med J Aust*. 2011;194(2):65–67.
17. Hertrampf E, Cortés F, Erickson JD, et al. Consumption of folic acid-fortified bread improves folate status in women of reproductive age in Chile. *J Nutr*. 2003;133(10):3166–3169.
18. Modjadji SEP, Alberts M, Mamabolo RL. Folate and iron status of South African non-pregnant rural women of childbearing age, before and after fortification of foods. *S Afr J Clin Nutr*. 2007;20(3):89–93.
19. Global Fortification Data Exchange. Global Fortification Data Exchange [database]. <https://fortificationdata.org/map-nutrient-levels-in-fortification-standards/#>. Accessed December 17, 2020.
20. Kancherla V, Wagh K, Johnson Q, et al. A 2017 global update on folic acid-preventable spina bifida and anencephaly. *Birth Defects Res Prev*. 2018;110(14):1139–1147.
21. Kancherla V, Wagh K, Pachón H, et al. A 2019 global update on folic acid-preventable spina bifida and anencephaly. *Birth Defects Res*. 2021;113(1):77–89.
22. Berihu BA, Welderufael AL, Berhe Y, et al. High burden of neural tube defects in Tigray, northern Ethiopia: hospital-based study. *PLoS One*. 2018;13(11):e0206212.
23. Blencowe H, Kancherla V, Moorthie S, et al. Estimates of global and regional prevalence of neural tube defects for 2015: a systematic analysis. *Ann N Y Acad Sci*. 2018;1414(1):31–46.
24. Castillo-Lancellotti C, Tur JA, Uauy R. Impact of folic acid fortification of flour on neural tube defects: a systematic review. *Public Health Nutr*. 2013;16(5):901–911.
25. Centeno Tablante E, Pachón H, Guetterman HM, et al. Fortification of wheat and maize flour with folic acid for population health outcomes. *Cochrane Database Syst Rev*. 2019;7(7):CD012150.
26. Keats EC, Neufeld LM, Garrett GS, et al. Improved micronutrient status and health outcomes in low- and middle-income countries following large-scale fortification: evidence from a systematic review and meta-analysis. *Am J Clin Nutr*. 2019;109(6):1696–1708.
27. Atta CA, Fiest KM, Frolkis AD, et al. Global birth prevalence of spina bifida by folic acid fortification status: a systematic review and meta-analysis. *Am J Public Health*. 2016;106(1):e24–e34.
28. Tessema M, Moges T, Zerfu D, et al. *Preventing Neural Tube Defects in Ethiopia: An Issue Brief*. Addis Ababa, Ethiopia: Ethiopian Public Health Institute; 2019.
29. Agoristas T, Vandvik P, Neumann I, et al. Finding current best evidence. In: Guyatt G, Drummond R, Meade MO, et al., eds. *Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice*. 3rd ed. New York, NY: McGraw-Hill; 2015:29–50.
30. Burns PA, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. *Plast Reconstr Surg*. 2011;128(1):305–310.
31. Paul M, Leibovici L. Systematic review or meta-analysis? Their place in the evidence hierarchy. *Clin Microbiol Infect*. 2014;20(2):97–100.
32. Guyatt G, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924–926.
33. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-grade evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383–394.
34. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol*. 2011;64(12):1311–1316.
35. Murad MH, Asi N, Alsawas M, et al. New evidence pyramid. *Evid Based Med*. 2016;21(4):125–127.
36. Diez Roux AV. The unique space of epidemiology: drawing on the past to project into the future. *Am J Epidemiol*. 2019;188(5):886–889.
37. Frieden TR. Evidence for health decision making—beyond randomized, controlled trials. *N Engl J Med*. 2017;377(5):465–475.
38. Stoltzfus RJ. How can the scientific community support the generation of the evidence needed to improve the quality of

- guidelines for micronutrient interventions? *Adv Nutr*. 2014; 5(1):40–45.
39. Vandenbroucke JP, Broadbent A, Pearce N. Causality and causal inference in epidemiology: the need for a pluralistic approach. *Int J Epidemiol*. 2016;56(6):1776–1786.
 40. Victora CG, Habicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. *Am J Public Health*. 2004;94(3):400–405.
 41. Hill AB. The environment and disease: association or causation? *Proc R Soc Med*. 1965;58(5):295–300.
 42. Lucas RM, McMichael AJ. Association or causation: evaluating links between environment and disease. *Bull World Health Organ*. 2005;83(10):792–795.
 43. Botto LD, Moore CA, Khoury MK, et al. Neural-tube defects. *N Engl J Med*. 1999;341(20):509–519.
 44. Noor RA, Abioye AI, Ulenga N, et al. Large-scale wheat flour folic acid fortification program increases plasma folate levels among women of reproductive age in urban Tanzania. *PLoS One*. 2017;12(8):e0182099.
 45. Engle-Stone R, Nankap M, Ndjebayi AO, et al. Iron, zinc, folate, and vitamin B-12 status increased among women and children in Yaoundé and Douala, Cameroon, 1 year after introducing fortified wheat flour. *J Nutr*. 2017;147(7):1–11.
 46. Schultz JT, Vatucawaqa PT. *Impact of Iron Fortified Flour in Child Bearing Age (CBA) Women in Fiji: 2010 Report*. Suva, Fiji: National Food and Nutrition Centre; 2012. <https://static1.squarespace.com/static/5e1df234eef02705f5446453/t/5f7cc2a5ab3e6e1b39c4305e/1602011884289/Fiji.pdf>. Accessed December 17, 2020.
 47. Abdollahi Z, Elmadfa I, Djazayery A, et al. Efficacy of flour fortification with folic acid in women of childbearing age in Iran. *Ann Nutr Metab*. 2011;58(3):188–196.
 48. Amarin ZO, Obeidat AZ. Effect of folic acid fortification on the incidence of neural tube defects. *Paediatr Perinat Epidemiol*. 2010;24(4):349–351.
 49. Barboza-Arguello MD, Umaña-Solís LM, Azofeifa A, et al. Neural tube defects in Costa Rica, 1987–2012: origins and development of birth defect surveillance and folic acid fortification. *Matern Child Health J*. 2015;19(3):583–590.
 50. Safdar OY, Al-Dabbagh AA, Abueliensen WA, et al. Decline in the incidence of neural tube defects after the national fortification of flour (1997–2005). *Saudi Med J*. 2007;28(8):1227–1229.
 51. Sayed A-R, Bourne D, Pattinson R, et al. Decline in the prevalence of neural tube defects following folic acid fortification and its cost-benefit in South Africa. *Birth Defects Res A Clin Mol Teratol*. 2008;82(4):211–216.
 52. Williams LJ, Mai CT, Edmonds LE, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. *Teratology*. 2002; 66(1):33–39.
 53. de Wals P, Tairou F, van Allen M, et al. Reduction in neural-tube defects after folic acid fortification in Canada. *N Engl J Med*. 2007;357(2):135–142.
 54. Williams LJ, Mai CT, Mulinare J, et al. Updated estimates of neural tube defects prevented by mandatory folic acid fortification—United States, 1995–2011. *MMWR Morb Mortal Wkly Rep*. 2015;64(1):1–5.
 55. World Health Organization. *Guideline: Optimal Serum and Red Blood Cell Folate Concentrations in Women of Reproductive Age for Prevention of Neural Tube Defects*. Geneva, Switzerland: World Health Organization; 2015. https://apps.who.int/iris/bitstream/handle/10665/161988/9789241549042_eng.pdf;jsessionid=2897B5EEF540AA
 56. Crider KS, Devine O, Hao L, et al. Population red blood cell folate concentrations for prevention of neural tube defects: Bayesian model. *BMJ*. 2014;349:g4554.
 57. Food Fortification Initiative. *Evidence for Fortification of Wheat Flour With Folic Acid and Vitamin B12*. Atlanta, GA: Food Fortification Initiative; 2018. https://static1.squarespace.com/static/5e1df234eef02705f5446453/t/5f8dba8ec5cdd07824ef7687/1603123863661/Evidence_FolicAcid_B12.pdf. Accessed April 30, 2020.
 58. Beckett EL, Martin C, Boyd L, et al. Reduced plasma homocysteine levels in elderly Australians following mandatory folic acid fortification—a comparison of two cross-sectional cohorts. *J Nutr Intermed Metab*. 2017;8: 14–20.
 59. Britto JC, Cançado R, Guerra-Shinohara EM. Concentrations of blood folate in Brazilian studies prior to and after fortification of wheat and cornmeal (maize flour) with folic acid: a review. *Rev Bras Hematol Hemoter*. 2014;36(4): 275–286.
 60. Centers for Disease Control and Prevention. Folate status in women of childbearing age, by race/ethnicity—United States, 1999–2000. *MMWR*. 2002;51(36):808–810.
 61. Enquobahrie DA, Feldman HA, Hoelscher DH, et al. Serum homocysteine and folate concentrations among a US cohort of adolescents before and after folic acid fortification. *Public Health Nutr*. 2012;15(10):1818–1826.
 62. Liu S, West R, Randell E, et al. A comprehensive evaluation of food fortification with folic acid for the primary prevention of neural tube defects. *BMC Pregnancy Childbirth*. 2004; 4(1):Article 20.
 63. Pfeiffer CM, Hughes JP, Lacher DA, et al. Estimation of trends in serum and RBC folate in the U.S. population from pre- to postfortification using assay-adjusted data from the NHANES 1988–2010. *J Nutr*. 2012;142(5):886–893.
 64. Pfeiffer CM, Sternberg MR, Zhang M, et al. Folate status in the US population 20 y after the introduction of folic acid fortification. *Am J Clin Nutr*. 2019;110(5): 1088–1097.
 65. Ray JG, Vermeulen MJ, Langman LJ, et al. Persistence of vitamin B12 insufficiency among elderly women after folic acid food fortification. *Clin Biochem*. 2003;36(5): 387–391.
 66. Hilder L. *Neural Tube Defects in Australia, 2007–2011: Before and After Implementation of the Mandatory Folic Acid Fortification Standard B12*. Sydney, New South Wales, Australia: University of New South Wales; 2016. <http://NationalPerinatalEpidemiologyandStatisticsUnit>. Accessed December 17, 2020.
 67. Westreich D, Edwards JK, Lesko CT, et al. Target validity and the hierarchy of study designs. *Am J Epidemiol*. 2018; 188(2):438–443.
 68. Hoddinott J. The investment case for folic acid fortification in developing countries. *Ann N Y Acad Sci*. 2018;1414(1):72–81.
 69. Horton S, Alderman H, Rivera JA. *Copenhagen Consensus 2008 Challenge Paper: Hunger and Malnutrition*. Tewksbury, MA: Copenhagen Consensus Center; 2008. https://www.copenhagenconsensus.com/sites/default/files/CP_Malnutrition_and_Hunger_-_Horton.pdf. Accessed December 17, 2020.
 70. Centers for Disease Control and Prevention. Ten great public health achievements—United States, 2001–2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(19):619–623.